ProCE Banner Activity

Highlights From the 2022 Society for Melanoma Research Annual Congress

Clinical Thought
Learn about highlights from key presentations at the 2022 Society for Melanoma Research Annual Congress.

Released: November 17, 2022

Expiration: November 16, 2023

No longer available for credit.

Share

Faculty

Michael A. Davies

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Michael A. Davies, MD, PhD: consultant/advisor/speaker: ABM Therapeutics, Bristol-Myers Squibb, Eisai, Iovance, Novartis, Pfizer, Roche/Genentech; researcher: ABM Therapeutics, Lead Pharma.